$3.25
0.08[2.52%]
At close: Apr 25
$3.25
0[0.00%]
PreMarket: 7:55PM EDT
Leap Therapeutics
(NASDAQ:LPTX)Leap Therapeutics Stock (NASDAQ:LPTX), Analyst Ratings, Price Targets, Predictions
Leap Therapeutics Inc has a consensus price target of $11.38, established from looking at the 20 latest analyst ratings. The last 3 analyst ratings were released from Baird, HC Wainwright & Co., and Mizuho on March 19, 2024, March 19, 2024, and November 20, 2023. With an average price target of $9.33 between Baird, HC Wainwright & Co., and Mizuho, there's an implied 187.18% upside for Leap Therapeutics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Baird
HC Wainwright & Co.
Mizuho
Raymond James
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Leap Therapeutics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 03/19/2024 | LPTX | Buy Now | Leap Therapeutics | $3.25 | 176.92% | Baird | Joel Beatty | $11 → $9 | Maintains | Outperform | Get Alert |
| 03/19/2024 | LPTX | Buy Now | Leap Therapeutics | $3.25 | 115.38% | HC Wainwright & Co. | Swayampakula Ramakanth | → $7 | Reiterates | Buy → Buy | Get Alert |
| 11/20/2023 | LPTX | Buy Now | Leap Therapeutics | $3.25 | 269.23% | Mizuho | Mara Goldstein | $20 → $12 | Maintains | Buy | Get Alert |
| 11/14/2023 | LPTX | Buy Now | Leap Therapeutics | $3.25 | 438.46% | Raymond James | Steven Seedhouse | $18.5 → $17.5 | Maintains | Outperform | Get Alert |
| 08/15/2023 | LPTX | Buy Now | Leap Therapeutics | $3.25 | 515.38% | Baird | Joel Beatty | $30 → $20 | Maintains | Outperform | Get Alert |
| 08/15/2023 | LPTX | Buy Now | Leap Therapeutics | $3.25 | 115.38% | HC Wainwright & Co. | Swayampakula Ramakanth | $2.5 → $7 | Maintains | Buy | Get Alert |
| 07/13/2023 | LPTX | Buy Now | Leap Therapeutics | $3.25 | 469.23% | Raymond James | Steven Seedhouse | $17 → $18.5 | Maintains | Outperform | Get Alert |
| 06/23/2023 | LPTX | Buy Now | Leap Therapeutics | $3.25 | 423.08% | Raymond James | Steven Seedhouse | $20 → $17 | Maintains | Outperform | Get Alert |
| 05/16/2023 | LPTX | Buy Now | Leap Therapeutics | $3.25 | -23.08% | HC Wainwright & Co. | Swayampakula Ramakanth | → $25 | Reiterates | Buy → Buy | Get Alert |
| 04/13/2023 | LPTX | Buy Now | Leap Therapeutics | $3.25 | -38.46% | Mizuho | Mara Goldstein | → $20 | Reiterates | → Buy | Get Alert |
| 03/27/2023 | LPTX | Buy Now | Leap Therapeutics | $3.25 | -23.08% | HC Wainwright & Co. | Swayampakula Ramakanth | → $25 | Reiterates | → Buy | Get Alert |
| 03/27/2023 | LPTX | Buy Now | Leap Therapeutics | $3.25 | -38.46% | Raymond James | Steven Seedhouse | $25 → $20 | Maintains | Outperform | Get Alert |
| 03/17/2023 | LPTX | Buy Now | Leap Therapeutics | $3.25 | -38.46% | Mizuho | Mara Goldstein | $30 → $20 | Maintains | Buy | Get Alert |
| 01/27/2023 | LPTX | Buy Now | Leap Therapeutics | $3.25 | -7.69% | Mizuho | Mara Goldstein | $60 → $30 | Maintains | Buy | Get Alert |
| 01/18/2023 | LPTX | Buy Now | Leap Therapeutics | $3.25 | -23.08% | HC Wainwright & Co. | Swayampakula Ramakanth | $40 → $25 | Maintains | Buy | Get Alert |
| 11/11/2022 | LPTX | Buy Now | Leap Therapeutics | $3.25 | -23.08% | Raymond James | Steven Seedhouse | $35 → $25 | Maintains | Outperform | Get Alert |
| 08/15/2022 | LPTX | Buy Now | Leap Therapeutics | $3.25 | 7.69% | Raymond James | Steven Seedhouse | $30 → $35 | Maintains | Outperform | Get Alert |
| 07/13/2022 | LPTX | Buy Now | Leap Therapeutics | $3.25 | -7.69% | Raymond James | Steven Seedhouse | $40 → $30 | Maintains | Outperform | Get Alert |
| 10/04/2021 | LPTX | Buy Now | Leap Therapeutics | $3.25 | 84.62% | Mizuho | Mara Goldstein | — | Initiates | → Buy | Get Alert |
FAQ
What is the target price for Leap Therapeutics (LPTX)?
The latest price target for Leap Therapeutics (NASDAQ: LPTX) was reported by Baird on March 19, 2024. The analyst firm set a price target for $9.00 expecting LPTX to rise to within 12 months (a possible 176.92% upside). 9 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Leap Therapeutics (LPTX)?
The latest analyst rating for Leap Therapeutics (NASDAQ: LPTX) was provided by Baird, and Leap Therapeutics maintained their outperform rating.
When was the last upgrade for Leap Therapeutics (LPTX)?
There is no last upgrade for Leap Therapeutics.
When was the last downgrade for Leap Therapeutics (LPTX)?
There is no last downgrade for Leap Therapeutics.
When is the next analyst rating going to be posted or updated for Leap Therapeutics (LPTX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Leap Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Leap Therapeutics was filed on March 19, 2024 so you should expect the next rating to be made available sometime around March 19, 2025.
Is the Analyst Rating Leap Therapeutics (LPTX) correct?
While ratings are subjective and will change, the latest Leap Therapeutics (LPTX) rating was a maintained with a price target of $11.00 to $9.00. The current price Leap Therapeutics (LPTX) is trading at is $3.25, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.